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Abstract.  
Objectives: The ADAMs (a disintegrin and metalloproteinase) enzymes compose a family of membrane-bound 
proteins characterized by their multi-domain structure and ADAM-12 expression is elevated in human non-small 
cell lung cancers. The aim of this study was to investigate the roles played by ADAM-12 in critical steps of 
bronchial cell transformation during carcinogenesis. Materials and methods: To assess the role of ADAM-12 in 
tumorigenicity BEAS-2B cells were transfected with a plasmid encoding human full-length ADAM-12 cDNA, 
and then the effects of ADAM-12 overexpression on cell behaviour were explored. Treatment of clones with 
heparin-binding epidermal growth factor (EGF)-like growth factor (HB-EGF) neutralizing antibodies as well as 
an EGFR inhibitor allowed the dissection of mechanisms regulating cell proliferation and apoptosis. Results: 
Overexpression of ADAM-12 in BEAS-2B cells promoted cell proliferation. ADAM-12 overexpressing clones 
produced higher quantities of HB-EGF in their culture medium which may rely on membrane-bound HB-EGF 
shedding by ADAM-12. Targeting HB-EGF activity with a neutralizing antibody abrogated enhanced cell 
proliferation in the ADAM-12 overexpressing clones. In sharp contrast, targeting of amphiregulin, EGF or 
transforming growth factor-α failed to influence cell proliferation; moreover, ADAM-12 transfectants were 
resistant to etoposide-induced apoptosis and the use of a neutralizing antibody against HB-EGF activity restored 
rates of apoptosis to be similar to controls. Conclusions: ADAM-12 contributes to enhancing HB-EGF shedding 




Together with snake venom metalloproteinases and ADAMTS (ADAMs with thrombospondin motifs), ADAMs 
(a disintegrin and metalloproteinase) constitute the adamalysin subfamily of metalloproteinases (Huovila et al. 
2005; Lu et al. 2005). ADAMs are membrane-bound proteins with a multi-domain structure, which participate in 
many physiological and pathological functions. One important role of ADAMs relates to their metalloproteinase 
domain, which endows them with the ability to shed membrane-bound growth factors [e.g. tumour necrosis 
factor-α or transforming growth factor-α (TGF-α); Black et al. 1997; Peschon et al. 1998] or other cell surface 
molecules, including ligands and receptors (Asakura et al. 2002; Maretzky et al. 2005). These events mediate 
intracellular pathways and signalling. ADAM-12, initially described as meltrin-α (Yagami-Hiromasa et al. 
1995), comprises an active metalloproteinase domain (Loechel et al. 1998) enabling shedding of growth factors, 
binding proteins (e.g. HB-EGF or IGFBP3; Loechel et al. 2000; Shi et al. 2000; Asakura et al. 2002; 
Higashiyama & Nanba 2005) and extracellular matrix components (Roy et al. 2004). The pro-domain (which 
remains non-covalently associated with the mature molecule) may rule ADAM-12 activities not only inside the 
cell, but also in the extracellular environment (Wewer et al. 2006). Two isoforms of ADAM-12 arise from 
alternative splicing: the secreted (short) form (ADAM-12S) which lacks transmembrane and cytoplasmic 
domains and the membrane-bound (long) form (ADAM-12L) (Gilpin et al. 1998). The short secreted form of 
ADAM-12 is, however, not expressed in lung tissue (Rocks et al. 2006). 
Having first been described as a homologue of ADAM-1 and -2 displaying similar effects in myoblast fusion 
(Yagami-Hiromasa et al. 1995), ADAM-12 was shown to be implicated in cell-cell and cell-matrix interactions 
leading to myogenesis (Gilpin et al. 1998) or adipogenesis (Kawaguchi et al. 2002; Masaki et al. 2005). The 
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cystein-rich domain of ADAM-12 supports mesenchymal cell adhesion through syndecans, and further spreading 
through integrin βl (Iba et al. 2000). Furthermore, it appears that the cystein-rich domain of ADAM-12 is 
important in supporting tumour cell adhesion using heparin sulfate proteoglycans as receptors or co-receptors 
(Iba et al. 1999). 
ADAM-12, produced in high amounts in placental tissue (Gilpin et al. 1998) and also present in maternal serum 
during pregnancy, has been proposed as a good early marker to predict the presence of Down syndrome 
(Laigaard et al. 2006), foetal trisomy 18 (Laigaard et al. 2005a) or pre-eclampsia, during the first trimester of 
pregnancy (Gack et al. 2005; Laigaard et al. 2005b). 
Given its multiple functions, it is conceivable that this proteinase could be linked to various pathologies, such as 
cancer development and progression. Indeed, ADAM-12 expression is up-regulated in various tumours (Le Pabic 
et al. 2003; Carl-McGrath et al. 2005; Kveiborg et al. 2005; Lendeckel et al. 2005; Rocks et al. 2006) and can be 
detected in urine from breast or bladder cancer patients, where its levels correlate with disease stage (Frohlich et 
al. 2006; Roy et al. 2004). In a murine mammary cancer model, ADAM-12 overexpression is linked to enhanced 
tumour progression (Kveiborg et al. 2005). Moreover, ADAM-12 transgenic mice display less apoptosis of 
tumour cells while stromal cells display increased sensitivity to apoptotic signals (Kveiborg et al. 2005). Several 
studies have described ADAMs, including ADAM-12, as being key enzymes in epidermal growth factor receptor 
(EGFR) transactivation signalling by shedding EGFR ligands (Yan et al. 2002; Lemjabbar et al. 2003; Sahin et 
al. 2004; Schafer et al. 2004; Itoh et al. 2005; Tanaka et al. 2005; Liu et al. 2006). Indeed, shedding of HB-EGF 
by ADAM-12 plays an important role in cardiac hypertrophy (Asakura et al. 2002). However, to date, 
mechanisms implicating ADAM-12 in lung cancer progression have not been studied at the molecular level. 
We recently described human full-length ADAM-12 overexpression in human non-small cell lung carcinoma 
(Rocks et al. 2006). This prompted us to decipher the exact roles of ADAM-12 in cancer development and 
progression, by transfection of immortalized bronchial epithelial cells (BEAS-2B cell line) with human full-
length ADAM-12. Here, we show that overexpression of ADAM-12 leads to an increase in cell proliferation 
while etoposide-stimulated apoptosis is reduced in cells transfected with ADAM-12. These effects are mediated 
through increased pro-HB-EGF shedding in cells overexpressing ADAM-12. 
MATERIALS AND METHODS 
Cell culture 
Human BEAS-2B cells (a bronchial epithelial cell line resulting from immortalization of bronchial epithelial 
cells by SV40) were obtained from the American Type Culture Collection (Manassas, VA, USA). Cells were 
grown in Airway Epithelial Cell Basal Medium (Promocell, Belgium) supplemented with Supplement Pack 
(Promocell, Heidelberg, Germany), 100 IU/mL penicillin and 100 µg/mL streptomycin (Invitrogen Corporation, 
Paisley, UK) at 37 °C in a humidified 5% CO2 atmosphere. 
Stable transfection of BEAS-2B cells with human ADAM-12L cDNA 
BEAS-2B cells, which spontaneously express very low amounts of ADAM-12L (Rocks et al. 2006), were stably 
transfected with pcDNA3-neo plasmid encoding human full-length ADAM-12L cDNA, kindly provided by Ulla 
Wewer (Copenhagen, Denmark). As controls, parental BEAS-2B cells were transfected with the empty 
pcDNA3-neo vector containing only the neomycin resistance gene. Transfection was performed by 
electroporation at 250 V and 960 µF using a gene pulser system (Bio-Rad Laboratories, Hercules, CA, USA). 
Culture of transfected cells in neomycin-containing medium (G418, 0.5 mg/mL; Life Technologies, Grand 
Island, NY, USA) allowed selection of clones, and all those obtained were screened by RT-PCR for their 
ADAM-12 expression. Selected clones were assessed by qRT-PCR and flow cytometry for their ADAM-12 
mRNA expression and protein production. Stable transfectants were grown in G418-containing medium           
(0.1 mg/mL; Invitrogen Corporation). 
Semi-quantitative RT-PCR analysis and real-time quantitative PCR 
For semi-quantitative RT-PCR, total RNA was extracted from cells by RNA Easy Qiagen kit as recommended 
by the manufacturer (Qiagen, Germantown, MD, USA). RT-PCR was performed on 10 ng of total RNA using 
the GeneAmp thermostable RNA RT-PCR Kit (Applied Biosystems, Foster City, CA, USA). Forward and 
reverse primers were designed as follow: ADAM-9 (forward 5'-AGAAGAGCTGTCTTGCCACAGA-3', reverse 
5'-TTTTCCCGCCACT-GCACGAAGT-3'); ADAM-12 (forward 5'-TTGGCTTTGGAGGAAGCACAGA-3', 
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reverse 5'-TTGAGGGGTCTGCTGATGTCAA-3'); ADAM-17 (forward 5'-TACAAAGGAAGCTGAC-
CTGGTT-3', reverse 5'-TTCATCCACCCTCGAGTTCCCA-3')· Samples were separated by acrylamide gel 
electrophoresis and were stained with Gel Star (Cambrex, Verviers, Belgium) and intensity of each band was 
measured using Quantity One software (Bio-Rad Laboratories, Hercules, CA, USA). In order to normalize 
mRNA levels in different samples, value of the band corresponding to each mRNA level was divided by 
intensity of the corresponding 28S rRNA value. 
For qRT-PCR, clones and parental BEAS-2B cells were cultured for 24 h in standard culture medium. Total 
RNA was obtained using the TRIzol reagent (Invitrogen Corporation) and 100 ng of RNA were used for retro-
transcription. Real-time quantitative PCR for ADAM-12 was performed using Superscript Platinum SYBR 
Green Two-Step qRT-PCR with ROX (Invitrogen Corporation). In order to obtain a normalized target value, 
actin gene was used as control. Results were calculated as mean + SEM of relative gene expression expressed as 
folds 2-(∆∆Ct) compared to parental BEAS-2B cells. 
Flow cytometry analysis 
Clones and parental BEAS-2B cells were cultured for 24 h in standard culture medium. The epithelial layer was 
dissociated with phosphate-buffered saline-ethylenediaminetetraacetic acid (5 mM) solution, and cells were 
detached by scraping. Epithelial cells were centrifuged and re-suspended in phosphate-buffered saline with 2% 
foetal calf serum. Cells were incubated with rabbit immunoglobulin G (IgG) anti-ADAM-12 (N-terminal 
domain) or normal rabbit IgG (2 µg/mL; Abeam, Cambridge, MA, USA) with or without permeabilization with 
the Perm-Wash kit (BD Biosciences, San Diego, CA, USA). After washing, antibody binding was detected with 
phycoerythrin-conjugated goat anti-rabbit IgG (Invitrogen Corporation). Cells were then washed, fixed in 
paraformaldehyde and 5000 events were analysed on a FACScalibur flow cytometer with CellQuest software 
(Becton Dickinson, Erebodegem, Belgium). Results are expressed as the difference between median 
fluorescence intensity (MFI) with specific antibody minus the isotype control MFI (∆MFI). 
Preparation of conditioned media and Western blot analysis 
For conditioned media, 106 cells were seeded on 100 mm diameter dishes, in standard culture medium for 24 h 
and then were cultured for 48 h in 6 mL of serum-free medium. Conditioned media were collected, clarified by 
centrifugation and stored at -20 °C. For Western blotting, samples were separated on 12% polyacrylamide gels 
and were transferred on polyvinylidene difluoride membranes. Samples were blocked for 2 h and then were 
incubated with anti-human HB-EGF goat polyclonal antibody (1/1000; R&D Systems, Minneapolis, MN, USA) 
overnight at 4 °C. Signals were detected by secondary horse radish peroxidase-coupled rabbit anti-goat antibody 
(DAKO, Glostrup, Denmark) diluted 1/1000 by using an enhanced chemiluminescence kit (PerkinElmer Life 
Sciences, Boston, MA, USA). 
Proliferation assay 
The cells were cultured in triplicate in 24-well plates at a density of 104 cells per well and were maintained in 
standard culture conditions. Cells were harvested each day for 1 week until confluence was reached. Fluorimetric 
DNA titration was then performed as described previously (Labarca & Paigen 1980) and used as an indicator of 
cell density. Anchorage-independent growth was determined by soft agar analysis (Laboisse et al. 1981) and 
cells were plated into 24-well plates at a density of 2 x 104 cells per well, in growth medium containing 0.3% 
agar, on the surface of a 0.6% agar gel. After 9 days of culture, cells were stained with crystal violet for 1 h and 
were photographed. Colonies were counted under a microscopic field at 2x magnification. Each assay was 
performed in triplicate on two independent assays. 
To investigate proliferation of cells treated with antibodies neutralizing the effects of EGFR ligands 
(amphiregulin, EGF, HB-EGF or TGF-α), or with an EGFR inhibitor, clones were seeded in triplicate into 96-
well plates at a density of 1250 cells per well. After adhesion, cells were cultured in standard culture medium or 
were treated either with anti-human HB-EGF (5 µg/mL; R&D Systems), anti-human amphiregulin (10 µg/mL; 
R&D Systems), anti-human EGF (8 µg/mL; R&D Systems), anti-human TGF-α (0.5 µg/mL; R&D Systems) 
neutralizing antibodies or with an EGFR inhibitor [4-(3-chloroanilino)-6,7-dimethoxyquinazoline] (AG1478; 5 
µg/mL; Calbiochem, San Diego, CA, USA). Quantification of cell proliferation was performed at days 0, 1, 2, 4 
and 6 by measuring 5-bromo-2'-deoxyuridine (BrdU) incorporation during DNA synthesis, following the 
manufacturer's instructions (Roche Diagnostics GmbH, Mannheim, Germany). Results are expressed as time-
dependent BrdU incorporation measured by chemiluminescence (absorbance A450 nm-A690 urn). 
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Invasion or migration capacities of cells using Boyden chamber assays 
In vitro migration properties of transfected cells were assessed using a modified Boyden chamber assay. Cells 
(104 cells per well) were suspended in serum-free medium supplemented with 0.1% bovine serum albumin and 
were placed in quadruplicate in the upper compartment of a 48-well invasion chamber (Nucleopore, Pleasanton, 
CA, USA). The lower compartment of the chamber was filled with 30 µL Airway Epithelial Cell Basal Medium 
containing 10% foetal bovine serum and 1% bovine serum albumin. For investigation of invasive properties, 
cells were allowed to migrate through filters with 8 µm pores (Nucleopore) pre-coated with 25 µg of Matrigel. 
After 24 h incubation at 37 °C in a humid atmosphere, filters were fixed with methanol at -20 °C and were 
stained with Giemsa solution (Fluka Chemie AG, Buchs, Switzerland) for 20 min. Non-migrating cells were 
removed by gentle wiping. Cells recovered from the lower surface of the filters were counted using a 
microscope, at 400 x magnification (30 fields). Experiments were performed twice in quadruplicate. Data are 
expressed as mean + SEM. 
Apoptosis measured by TUNEL assay 
BEAS-2B cells and transfected clones were seeded at 5 x 104 cells per well, in triplicate into 24-well plates. 
After adhesion, cells were either grown in standard culture medium or were stimulated with etoposide (20 µM; 
Calbiochem) for 24 h. They were then harvested for TUNEL staining. The proportion of cells showing DNA 
fragmentation was measured by incorporation of fluorescein isothiocyanate (FITC)-12-dUTP into DNA using 
terminal deoxynucleotidyltransferase (in situ Cell Death Detection, Roche Diagnostics GmbH) as described by 
the manufacturer. In order to determine total cell number, cell nuclei were labelled with bisbenzimide. Total 
number of cells and TUNEL-labelled cells were counted in six random fields at 400x magnification. Quantitative 
analysis of apoptosis is represented as the ratio of TUNEL-labelled cells to total number of cells. Experiments 
were performed at least twice in triplicate. 
To investigate the effects of HB-EGF neutralization on apoptosis, cells were seeded at 5 x 104 per well, in 
quadruplicate, into 24-well plates. After adhesion, they were either grown in standard culture medium or were 
treated with etoposide (20 µ M) alone, in combination with a general caspase inhibitor (10 µ M; Z-VAD-FMK, 
R&D Systems) or with an anti-HB-EGF neutralizing antibody (5 µg/mL), for 24 h. Cells were then harvested for 
TUNEL staining and apoptotic cells were counted. Experiments were performed twice in quadruplicate. 
Subcutaneous injection of clones into immunodeficient mice 
Matrigel was prepared as described previously (Noel et al. 1991). Transfected BEAS-2B clone suspensions    
(106 cells) were prepared in standard medium and mixed with an equal volume of cold Matrigel, just before 
subcutaneous injection into 6- to 8-week-old male SCID mice (Harlan, Indianapolis, IN, USA). A final volume 
of 400 µL of mixed Matrigel and medium-containing cells was injected into each flank of the mouse. 
Statistical analysis 
Data are expressed as mean + SEM. Differences between experimental groups were assessed using the Mann-
Whitney test. P < 0.05 (*), P < 0.01 (**) and P < 0.001 (***) were considered as statistically significant. 
RESULTS 
Transfection of BEAS-2B cells with full-length ADAM-12 and clone characterization 
As ADAM-12 mRNA was weakly expressed in the basal state of BEAS-2B cells (Rocks et al. 2006), we stably 
transfected this cell line with pcDNA3-neo vector containing full-length ADAM-12 cDNA (BA clones) or with 
the pcDNA3-neo plasmid containing only the neomycin resistance gene, serving as control (BV clones). Clones 
obtained by G418 selection were initially screened by RT-PCR. PCR reactions for the neomycin gene confirmed 
the presence of the pcDNA3-neo plasmid in transfected clones (data not shown). For further in vitro studies, four 
clones overexpressing ADAM-12 (referred to as BA clones) and four control clones (referred to as BV clones) 
were selected (Fig. la). Both real-time quantitative PCR and flow cytometry studies revealed higher ADAM-12 
mRNA expression (*P< 0.05 versus BV27) and protein production in BA clones than in BV control clones            
(*P < 0.05 versus BA17) or BEAS-2B cells (**P < 0.01 versus BA clones) (Fig. 1b,c). 
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Figure 1. Characterization and selection of transfectants. (a) Semi-quantitative PCR analysis of transfected clones. 
ADAM-12 mRNA expression is higher in cells transfected with ADAM-12 cDNA-containing pcDNA3 plasmid (BA) than in cells 
transfected with the empty vector used as control (BV). L: 200 bp molecular weight marker (Smart Ladder, Eurogentec, Belgium), (b) Real-
time quantitative PCR measuring ADAM-12 expression in clones. ADAM-12 expression is higher in ADAM-12 transfected clones than in 
control clones. Results are the mean ± SEM of relative gene expression expressed in folds (2-∆∆ct) compared with BEAS-2B gene expression          
(n = 3). *P < 0.05, Mann-Whitney test, (c) ADAM-12 protein production was determined by flow cytometry. ADAM-12 protein production 
is higher in ADAM-12 transfected clones than in control clones. Results are expressed as mean ± SEM of ∆MFI (difference between mean 




ADAM-12 overexpression increased cell proliferation in vitro 
Cell proliferation of clones and parental cells was first measured by determining DNA concentration as an 
indicator of cell density. Interestingly, ADAM-12 overexpressing clones displayed higher in vitro cell population 
growth rates than controls (Fig. 2a). It is worth noting that this difference in cell population growth rates was 
clearly apparent after 4 days of culture (*P < 0.05 versus BV27 and parental BEAS-2B cells). In addition, 
ADAM-12 overexpression also significantly enhanced anchorage-independent cell colony formation after 9 days 
of culture in soft agar (***P < 0.001 versus controls) (Fig. 2b,c). 
ADAM-12-mediated enhanced proliferation is dependent on exaggerated production of mature HB-EGF 
As HB-EGF is a key player in cell proliferation regulatory mechanisms and appears to be matured by ADAM-
dependent shedding, we sought a possible direct effect for ADAM-12 over-expression on HB-EGF maturation in 
clones. Protein levels of mature HB-EGF were higher in conditioned media from clones overexpressing 
membrane-bound ADAM-12 (BA clones), as compared to control clones (Fig. 3a). These differences were 
dependent on ADAM-12 over-expression and could not be ascribed to shedding of pro-HB-EGF by ADAM-9 or 
ADAM-17. Indeed ADAM-9 and ADAM-17 mRNA levels were similar in parental cells, ADAM-12 over-
expressing clones or control clones as assessed by RT-PCR (data not shown). 
We further addressed the effects of HB-EGF or EGF receptor tyrosine kinase inhibition on proliferation of 
ADAM-12 overexpressing clones and corresponding controls. When cells were cultured in standard media, in 
the presence of an anti-EGFR compound (AG1478) or an anti-HB-EGF neutralizing antibody, exaggerated 
proliferation found in ADAM-12 overexpressing clones was suppressed (**P < 0.01, ***P < 0.001, standard 
conditions versus inhibitors; °P < 0.05, °°P < 0.01 versus BV27) (Fig. 3b,c). This inhibitory effect in cell 
proliferation was not observed with neutralizing antibodies targeting amphiregulin, EGF or TGF-α (Fig. 3d). 
Taken together, these results showed that increase in ADAM-12-dependent cell proliferation was related to 
activation of the HB-EGF pathway. 
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Figure 2. In vitro proliferation of BEAS-2B clones, (a) Cells cultured in complete culture medium were incubated (in 
triplicate) in 24-well plates (104 cells/well) and cell number was determined by measuring DNA concentration at 1-day interval (n = 3); *P < 
0.05, BA17 and BA36 versus BV27 and parental BEAS-2B (B2B) cells, Mann-Whitney test. Results shown are those of a representative 
assay out of three different experiments, (b and c) Clones were grown in 24-well dishes in soft agar and cell growth was determined by 
counting number of colonies developed after 9 days of incubation. ADAM-12 overexpression significantly enhanced growth abilities of cells 
without any anchorage support (***P < 0.001 versus BV27 and BEAS-2B cells). Results are expressed as mean number of colonies counted 
per field at 2x magnification, Mann-Whitney test (results are representative of three independent experiments). 
 
Figure 3. Mature HB-EGF expression in clones overexpressing ADAM-12 and effects of HB-EGF 
inhibition on cell proliferation, (a) Mature (soluble) HB-EGF protein (sHB-EGF) production measured by Western blot analysis in 
conditioned media of transfected cells (top panel). Data expressed as relative sHB-EGF band intensities, considering BV27 intensity as 100% 
(lower panel), (b-d) Cells were grown either in standard media or in media supplemented with a specific inhibitor of EGF receptor tyrosine 
kinase (AG1478) (b) or an anti-HB-EGF neutralizing antibody (c), or neutralizing antibodies against amphiregulin (AR), EGF, TGF-α (d). 
Results are representative of three independent experiments. In (d), results are shown for BA36 clone, as a representative example. **P < 
0.01, ***P < 0.001 versus stimulation with inhibitors. °P < 0.05 versus BV27; °°P < 0.01 versus BV27, Mann-Whitney test. 
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ADAM-12 induces HB-EGF-dependent resistance to apoptosis 
To determine etoposide-induced apoptosis in BEAS-2B clones, an in vitro experiment was conducted using a 
TUNEL assay. Baseline apoptotic rate was determined in the cells cultured in standard conditions without any 
etoposide treatment. As shown in Fig. 4a, stimulation of BEAS-2B cells with etoposide significantly enhanced 
apoptosis when compared to baseline levels (ooP<0.01). In addition, when treated with etoposide, cells 
overexpressing ADAM-12 displayed significantly lower apoptosis than those transfected with the empty vector 
or in parental BEAS-2B cells (**P< 0.01) (Fig. 4a). As a control, cells were treated with the broad caspase 
inhibitor Z-VAD-FMK, which drastically diminished apoptosis, demonstrating a caspase-dependent mechanism 
for apoptosis in our model (Fig. 4b). Neutralizing HB-EGF antibody abrogated protection against apoptosis 
observed in ADAM-12 overexpressing cells (***P < 0.001, etoposide versus etoposide and HB-EGF inhibitor) 
(Fig. 4c). In sharp contrast, addition of anti-HB-EGF neutralizing antibody did not affect the apoptotic level of 
parental (P = 0.94) or control BV27 (P = 0.78) cells treated with etoposide. This result clearly underlines a role 
for ADAM-12 over-expression in protection of cells against apoptosis, through an HB-EGF-mediated 
mechanism. 
Figure 4. Representative results of TUNEL assay, measuring role of ADAM-12, in cell resistance to 
etoposide-induced apoptosis, effects of general caspase inhibition and HB-EGF neutralization, (a) Cells were 
immunostained with FITC-12-dUTP to investigate baseline or etoposide-induced apoptosis (presented data are representative of two 
independent experiments). Results are expressed as percentage of mean number of TUNEL-positive cells compared to total cell number for 
each group ± SEM. **P < 0.01, compared to parental or control transfected cells; °°P < 0.01, compared to baseline apoptosis in parental 
BEAS-2B cells, Mann-Whitney test, (b) Cells cultured in presence of a general caspase inhibitor and subjected to apoptosis inducing 
conditions showed reduced apoptotic levels when compared to standard apoptosis inducing experiments (*P<0.05, ***P< 0.001). (c) 
Inhibition of HB-EGF by a neutralizing antibody enhanced apoptotic levels of ADAM-12 overexpressing cells. Apoptotic levels in parental 
and control cells were not different when cells were cultured with etoposide alone or with etoposide and anti-HB-EGF neutralizing antibody, 
(d) Representative microphotographs of TUNEL staining in ADAM-12 overexpressing clones and controls. White arrows indicate examples 
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Role of ADAM-12 in in vitro cell migration and invasion 
In vitro cell migration or invasion capacities were compared between transfected cells using a modified Boyden 
chamber assay. Parental cells and clones were evaluated for their potential to migrate through filters or invade a 
Matrigel layer, for 24 h. In this assay, ADAM-12 overexpression did not affect cell migration or invasion (P > 
0.05) (data not shown). 
Subcutaneous injection of clones into immunodeficient mice 
To further evaluate the in vivo tumorigenic phenotype of ADAM-12 transfectants, clones were subcutaneously 
injected into immunodeficient SCID mice. However, neither the ADAM-12 transfected cells nor the control cells 
developed detectable tumours when injected into SCID mice (data not shown). These data suggest that ADAM-
12 was not per se sufficient to initiate cancer development. 
DISCUSSION 
Over the last number of years, matrix metalloproteinases have been studied extensively, and increased activity of 
these proteolytic enzymes has been associated with the malignant phenotype (Egeblad & Werb 2002; Rocks et 
al. 2008). ADAM-12 is a proteinase of the ADAM family which is highly expressed in rapidly growing tissues, 
such as placenta and malignant tumours (Iba et al. 1999; Le Pabic et al. 2003). Based on our previous studies 
showing overexpression of full-length ADAM-12 mRNA and proteins, in human non-small cell lung cancer 
samples (Rocks et al. 2006), we investigated the effects of full-length ADAM-12 overexpression on the 
phenotype of human bronchial epithelial non-transformed BEAS-2B cells. Here, we focused our attention on 
membrane-bound ADAM-12, because the short secreted form of ADAM-12 is expressed neither in lung tissue 
nor in lung tumours (Rocks et al. 2006). 
Both in vitro and in vivo studies were performed in order to characterize ADAM-12 transfected clones. 
Proliferation assays measuring cell density by DNA titration and BrdU incorporation revealed higher 
proliferation rates in ADAM-12 overexpressing clones as compared to control clones. 
Normally, numerous proteins are secreted as soluble molecules but some proteins playing key roles in cell 
behaviour, such as EGFR ligands, are first synthesized as membrane-bound precursors. These molecules require 
proteolytic cleavage through zinc-dependent proteinases for activation. ADAM proteinases, such as ADAM-9, -
12 and -17, are important regulators of cleavage for EGFR ligands (Gee & Knowlden 2003; Ohtsu et al. 2006). 
In order to provide further insight into the exaggerated cell proliferation levels found in ADAM-12 
overexpressing clones, we sought potential factors whose activation could be regulated by ADAM-12. Of 
interest was our finding of higher levels of soluble active HB-EGF in media conditioned by ADAM-12 over-
expressing cells, while production of other ligands of EGFR was not affected. Moreover, incubation of cells with 
an anti-HB-EGF blocking antibody or a specific inhibitor of EGFR reversed the enhanced cell proliferation in 
ADAM-12 overexpressing clones, confirming a role for this factor in control of proliferation of these cells. A 
specific effect on the HB-EGF/EGFR pathway is supported by failure of other neutralizing antibodies targeting 
amphiregulin, EGF or TGF-α, to control cell proliferation. These data are reinforced by previous studies showing 
the predominant role of HB-EGF shedding in glioblastoma or in HB-EGF-dependent cardiac hypertrophy. These 
studies suggested that processing of HB-EGF by ADAM-12 could play a central role in many pathological 
processes implicating cell proliferation (Asakura et al. 2002; Kodama et al. 2004). ADAM-9 and ADAM-17, 
two potentially important regulators of pro-HB-EGF shedding, are, however, not involved in the amplified HB-
EGF shedding observed in ADAM-12 transfectants. Indeed, no difference regarding their expression was found 
among the clones. 
A role for ADAM-12 in mechanisms leading to apoptosis has been suggested by previous authors, who reported 
lower apoptosis levels in tumour cells from ADAM-12 overexpressing mice (Kveiborg et al. 2005). In the 
present study, control clones were found to be more sensitive to etoposide-induced apoptosis than ADAM-12 
overexpressing clones. To challenge the hypothesis that higher, active HB-EGF production could help protect 
cells from apoptosis in our model, neutralizing antibodies of HB-EGF were used. Interestingly, neutralization of 
HB-EGF led to increased apoptosis. This is the first description of an anti-apoptotic effect of ADAM-12 through 
HB-EGF shedding in bronchial cells. Our study, therefore, clearly identifies ADAM-12 as a potential therapeutic 
target in cancer. It is interesting to note that etoposide is a chemotherapeutic drug used as a treatment option in 
some types of cancer, including lung cancer (Rigas & Kelly 2007). Data presented here argue for a possible role 
of ADAM-12 in chemoresistance against etoposide in vivo and imply a role for this enzyme in resistance of 
some tumours to chemotherapy regimens. These facts should be handled carefully and further experiments are 
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still needed to demonstrate that ADAM-12 inhibition, for example, by SiRNAs or neutralizing antibodies, can 
actually reverse this phenotype characteristic. 
ADAM-12 has been proposed as a reliable biomarker for bladder and breast cancer, because it can be detected in 
urine from breast cancer or bladder cancer patients, confirming the biological relevance of this mediator. Our 
data also suggest that HB-EGF is another potential target in bronchial cell lines and indicate that further research 
with a neutralizing antibody to HB-EGF or with an EGFR inhibitor should be conducted in vitro and in vivo. 
Because in vitro results converge towards a modification of the BEAS-2B cell phenotype, it seemed essential to 
analyse in vivo behaviour of cells. At the first attempt, a soft agar assay was applied to evaluate anchorage-
independent growth capacity of the cells, a major hallmark of transformed cells. Indeed, the ability of cells to 
proliferate without firm attachment is one of the in vitro indicators of tumorigenicity (Freedman & Shin 1974). 
Most cancer cells overcome anchorage growth dependency and become capable of non-anchored proliferation. 
In our work, ADAM-12 overexpression in BEAS-2B cells led to enhancement of their ability to form colonies 
during soft agar assay. These data pinpoint the impact of ADAM-12 overexpression on modulation of cell 
phenotype. In vivo tumorigenicity was then investigated by subcutaneously inoculating cell transfectants into 
immunodeficient SCID mice. Neither ADAM-12 transfected cells nor the control cells developed detectable 
tumours. Therefore, ADAM-12 expression was not per se sufficient to induce development of tumours in vivo. It 
is now well accepted that tumour progression is not only dependent on acquisition of new properties by tumour 
cells themselves, but is also influenced by the tumour microenvironment composed of extracellular matrix and 
host cells, including stromal cells (Kalluri & Zeisberg 2006; Noel et al. 2008). Despite inoculation of cells with 
Matrigel, known as a tumour promoter (Noel et al. 1993), results of the tumour implantation were unsuccessful. 
In addition, inoculation of cells into the lung by intratracheal instillation also failed to promote tumour 
development (data not shown). These data demonstrate that although ADAM-12 is able to control cell 
proliferation, it cannot convert immortalized non-transformed cells, such as BEAS-2B cells into tumorigenic 
cells. Moreover, ADAM-12 overexpressing clones did not display any invasive phenotype in vitro in modified 
Boyden chambers, suggesting again that ADAM-12 is not sufficient per se to acquire invasive properties. 
Interestingly, Kveiborg et al. described a higher frequency of metastasis in polyomavirus middle T oncoprotein 
transgenic mice expressing ADAM-12 (Kveiborg et al. 2005), suggesting that ADAM-12 confered increased 
malignancy in this mouse model, whose oncogenesis was induced by expression of the polyomavirus middle T 
oncoprotein. Hence, ADAM-12 might act as an enhancer of malignancy in cells which already have acquired a 
transformed phenotype, while it contributes to enhance the proliferation in non-transformed cells. 
In conclusion, we show for the first time that ADAM-12 overexpression in lung epithelial cells contributes to 
increased cell proliferation and reduced apoptosis. These effects appeared to be mediated through ADAM-12-
dependent pro-HB-EGF shedding and further EGFR transactivation. ADAM-12 should therefore, be considered 
as one of the key factors participating in the complex interplay between growth factors and proteinases. ADAM-
12 contributes to enhance cell proliferation levels and to reduce apoptosis thereupon endowing normal epithelial 
cells with tumour cell features. 
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